Date: 2014-04-24
Type of information: Financing round
Company: Isarna Therapeutics (Germany)
Investors: AT NewTec (Germany), Global Asset Funds (Germany), MIG Fonds (Germany)
Amount: € 5.5 million
Funding type: financing round
Planned used:
Others: * On April 24, 2014, Isarna Therapeutics, a leader in TGF-β therapeutics, has announced that it has raised € 5.5 million ($7.6M) in equity from its current investors including AT NewTec, Global Asset Funds, and MIG Fonds. The company also announced that Elizabeth Czerepak has joined Isarna’s management team as Chief Financial Officer and Chief Business Officer to lead the company’s new office location in New York City. Elizabeth Adkins Czerepak, MBA, brings to Isarna twenty-one years of pharmaceutical and biotechnology leadership experience and nine years as a venture capital investor at JP Morgan and Bear Stearns. Ms. Czerepak has served in executive-level finance, licensing and corporate development positions, most recently as Chief Financial Officer and Principal Accounting Officer at Cancer Genetics, Inc. (CGIX), that she took public on NASDAQ and for which she raised three rounds of public financing totaling $69M. Prior to CGI, Elizabeth worked at BASF Pharma (Knoll), Hoffmann-La Roche and Merck & Co. Isarna Therapeutics is developing TGF-β inhibitors that stimulate the human immune system to effectively fight cancer and other diseases.
Therapeutic area: Cancer - Oncology
